In the Greek cohort, NSCLC patients with high SOX2 tumor levels (n = 245, scores >193) had longer overall survival than subjects with low tumor SOX2 (Figure 4, median survival 42 vs. 21 months; log rank p = 0.0002,). The gene discussed is SOX2; the disease is neoplasm.